Intentions of Patients with Hypertension to Receive a Booster Dose of the COVID-19 Vaccine: A Cross-Sectional Survey in Taizhou, China

Abstract

COVID-19 patients with hypertension have increased hospital complications and mortality rates. Moreover, these patients also have lower antibody titers after receiving the coronavirus disease (COVID-19) vaccine. Therefore, patients with hypertension should receive a COVID-19 vaccine booster. To promote the uptake of COVID-19 vaccine booster among hypertensive patients, this study investigated patients’ willingness and factors that influence patients with hypertension to receive the COVID-19 vaccine booster. From July 2021 to August, 410 patients with hypertension were surveyed. Overall, 76.8% of patients were willing to receive the COVID-19 vaccine booster, as 82.7% of patients without comorbidities and 72.7% of patients with comorbidities were willing to receive the vaccine booster. The main factors that influenced the willingness of patients with hypertension to receive a booster dose were the preventive effect of the vaccine (χ2 = 52.827, p < 0.05), vaccine safety (χ2 = 42.423, p < 0.05), vaccine knowledge (χ2 = 7.831, p < 0.05), presence of comorbidities (χ2 = 4.862, p < 0.05), disease control (χ2 = 5.039, p < 0.05), and antihypertensive treatments (t = 12.565, p < 0.05). This study’s findings highlight the need to promote knowledge about booster vaccination among patients and health management. These measures would improve patients’ willingness and knowledge about the vaccine and their health status, which are the main factors that influence patients’ intention to receive booster vaccines.

Acceptance of COVID-19 boosters among hypertensive patients in China: A multicenter cross-sectional study

“… 14 Nevertheless, previous studies show that people with hypertension are less willing to get a dose of COVID-19 booster than people in general (76.8% vs 91.1%). 17 , 18 In general people, sociodemographic characteristics including age, gender, occupation, and education influence booster vaccine acceptance. 19 Confidence in the safety of the COVID-19 vaccines, and in the effectiveness of the COVID-19 vaccines against SARS-CoV-2 and its variants, significantly associated with willingness to accept COVID-19 booster.…”

“… 18 In the hypertensive population, the preventive effect of the vaccine, vaccine safety, vaccine knowledge, presence of comorbidities, disease control, and antihypertensive treatments were the main factors that influenced the willingness of patients with hypertension to receive a booster dose. 17 Following the COVID-19 policy change, the government has started the second dose of booster immunization on December 13, 2022. 20 Amid the evolving COVID-19 landscape, the US Food and Drug Administration (FDA) proposed switching to annual coronavirus vaccine, mimicking flu model, which could considerably lower the long-term risk of infection.…”

Understanding the impact of chronic diseases on COVID‐19 vaccine hesitancy using propensity score matching: Internet‐based cross‐sectional study

“…49.5% among patients with chronic diseases (Jiang et al, 2022;Kassa Mekonnen et al, 2022;Lin et al, 2022;Mejri et al, 2022;Peng et al, 2021;Tourkmani et al, 2022;Ying et al, 2022). It is clear that people with chronic diseases have a higher prevalence of COVID-19 vaccine hesitancy than the general population.…”

“…According to available surveys, the prevalence of COVID‐19 vaccine hesitancy ranges from 10.4% to 38.0% among the general population in different countries and regions (Gallè et al., 2021; Kc et al., 2022; Neumann‐Böhme et al., 2020; Reiter et al., 2020). However, the prevalence of COVID‐19 vaccine hesitancy ranged from 13.4% to 49.5% among patients with chronic diseases (Jiang et al., 2022; Kassa Mekonnen et al., 2022; Lin et al., 2022; Mejri et al., 2022; Peng et al., 2021; Tourkmani et al., 2022; Ying et al., 2022). It is clear that people with chronic diseases have a higher prevalence of COVID‐19 vaccine hesitancy than the general population.…”

“…Furthermore, past research has shown that chronic diseases have been recognized as a risk factor for COVID‐19 vaccine hesitancy in the United States, Australia and the United Kingdom (Huang et al., 2022; Kc et al., 2022). The main reasons for vaccine hesitancy in patients with chronic diseases were fear of adverse reactions (Cénat et al., 2023), concerns about vaccine safety (Ying et al., 2022), poor health (Wu et al., 2021), a lack of valid information (Lin et al., 2022) and the rapid development of vaccines (Campochiaro et al., 2021). Based on this, exploring the influencing factors is the key to establishing targeted vaccination measures for this vulnerable group.…”